Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective cohort study of carotid intima-media thickness after irradiation.
Wilbers J, Hoebers FJ, Boogerd W, van Werkhoven ED, Nowee ME, Hart G, Bartelink H, van Dijk EJ, Kappelle AC, Dorresteijn LD. Wilbers J, et al. Among authors: van dijk ej, van werkhoven ed. J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2701-2707. doi: 10.1016/j.jstrokecerebrovasdis.2014.06.009. Epub 2014 Oct 7. J Stroke Cerebrovasc Dis. 2014. PMID: 25304721
Factors associated with patient-reported cosmetic outcome in the Young Boost Breast Trial.
Brouwers PJ, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon J, Maduro JH, Russell NS, Scheijmans LJ, Schinagl DA, Westenberg AH, Poortmans P, Boersma LJ; Young Boost Trial research group. Brouwers PJ, et al. Among authors: van loon j, van werkhoven e. Radiother Oncol. 2016 Jul;120(1):107-13. doi: 10.1016/j.radonc.2016.04.017. Epub 2016 May 28. Radiother Oncol. 2016. PMID: 27247055 Clinical Trial.
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). van Ramshorst MS, et al. Among authors: van werkhoven e. Breast. 2016 Oct;29:153-9. doi: 10.1016/j.breast.2016.07.017. Epub 2016 Aug 5. Breast. 2016. PMID: 27498129 Clinical Trial.
Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, Schinagl D, Oei B, Rodenhuis CC, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan DA, Dubois JB, Remouchamps V, Mirimanoff RO, Hart G, Collette S, Collette L, Bartelink H; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups. Vrieling C, et al. Among authors: van werkhoven e, van limbergen e. JAMA Oncol. 2017 Jan 1;3(1):42-48. doi: 10.1001/jamaoncol.2016.3031. JAMA Oncol. 2017. PMID: 27607734 Clinical Trial.
Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.
van Ramshorst MS, van Werkhoven E, Mandjes IAM, Schot M, Wesseling J, Vrancken Peeters MTFD, Meerum Terwogt JM, Bos MEM, Oosterkamp HM, Rodenhuis S, Linn SC, Sonke GS. van Ramshorst MS, et al. Among authors: van werkhoven e. Eur J Cancer. 2017 Mar;74:47-54. doi: 10.1016/j.ejca.2016.12.023. Epub 2017 Feb 10. Eur J Cancer. 2017. PMID: 28335887 Clinical Trial.
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.
van Rossum AGJ, Kok M, McCool D, Opdam M, Miltenburg NC, Mandjes IAM, van Leeuwen-Stok E, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, van Werkhoven E, Schmidt MK, Oosterkamp HM, Linn SC. van Rossum AGJ, et al. Among authors: van bochove a, van werkhoven e, van leeuwen stok e. Oncotarget. 2017 Nov 27;8(69):113531-113542. doi: 10.18632/oncotarget.22697. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371927 Free PMC article.
Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial.
Brouwers PJAM, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon J, Maduro JH, Russell NS, Scheijmans LJEE, Schinagl DAX, Westenberg AH, Poortmans P, Boersma LJ; Young Boost Trial research group. Brouwers PJAM, et al. Among authors: van loon j, van werkhoven e. Radiother Oncol. 2018 Sep;128(3):434-441. doi: 10.1016/j.radonc.2018.06.020. Epub 2018 Jul 3. Radiother Oncol. 2018. PMID: 29980320 Clinical Trial.
138 results